Duplicate Therapy
Customize your policy alerts
Sign up for QualChoice Policy AR.QC.CP.PMN.04 alerts
Get alerted when Policy AR.QC.CP.PMN.04 changes without checking for updates manually.
Monitor payer policy activity
This policy governs pharmacy-level duplicate therapy edits that limit members from receiving multiple medications within the same or similar drug classes and defines prior authorization and documentation requirements for overrides; it applies to QualChoice Commercial membership unless state Medicaid overrides apply as noted.
Approval duration for therapy changes and dose titrations updated from 12 months to 30 days.
Coverage Criteria — Duplicate Therapy
Situations where duplicate therapy may be approved
Pharmacist may approve when at least one of the following applies:
Approval duration: 30 days for therapy changes and dose titration; approvals based on medical literature may be granted for 12 months when supported as standard of care.
Approval duration: 30 days for therapy changes and dose titration; approvals based on medical literature may be granted for 12 months when supported as standard of care.
Approval duration: 12 months when therapy is supported by medical literature and considered standard of care.
Not medically necessary — duplicate therapy without justification
Not covered when ALL of the following are true:
Such cases should be denied based on the restrictions identified by drug class.
For members covered by Medicaid, state Medicaid coverage provisions take precedence when they conflict with the coverage provisions in this clinical policy. Providers should consult the applicable state Medicaid manual for any differing coverage rules before seeking an override or prior authorization under this policy.
Requests that exceed the listed drug-class restrictions are considered not medically necessary and should be denied when the provider has not submitted documentation establishing medical necessity or a standard-of-care justification. If clinical justification is not provided, the case should be denied based on the restrictions identified by drug class.
Provider Actions, Prior Authorization, and Documentation
Prior authorization required for duplicate therapy
Prior authorization is required for any claim that triggers a duplicate therapy restriction; overrides are not available at point-of-sale and the request must be submitted for pharmacist review.
Pharmacist review and potential approval
A pharmacist will review prior authorization requests that exceed the class-specific duplicate therapy restrictions and may approve the request if it is medically necessary and within the standard of care.
- Pharmacist may approve when provider is changing therapy (discontinuing duplicate agent) — approval duration: 30 days
- Pharmacist may approve for multiple strengths for dose titration — approval duration: 30 days
- Pharmacist may approve when requested therapy is supported by medical literature as standard of care — approval duration: 12 months
Clinical supporting documentation required
Providers must submit supporting clinical documentation (for example, office chart notes, laboratory results, or other clinical information) with the prior authorization to establish medical necessity for duplicate therapy.
- Include office chart notes, lab results, or other relevant clinical information demonstrating medical necessity or standard-of-care justification.
Denial trigger when medical necessity not established
If the provider does not establish medical necessity or a standard-of-care justification, the request must be denied based on the drug-class restrictions.
Background and Rationale
Duplicate therapy edits are applied at the pharmacy level to prevent members from receiving excessive or overlapping medication regimens within the same or similar drug classes. These edits require pharmacist review and a prior authorization process to permit clinically justified exceptions such as therapy changes (including discontinuation of a duplicate agent) or dose titration. When approved for these reasons, approval durations for therapy changes and dose titrations default to 30 days, while therapies supported by medical literature and considered standard of care may be approved for longer durations.
Definitions
Initial Duplicate Therapy Constraints
Initial duplicate therapy constraints
Class-specific restriction summary
Pharmacist review and prior authorization required for exceptions.
Step Therapy / Pharmacist Review
| Step | Requirement |
|---|---|
| 1 | Pharmacist shall review prior authorization requests that exceed class-specific restrictions; pharmacist may approve the request if medically necessary and within standard of care. Examples include: provider changing therapy (discontinuing duplicate agent) — approval duration: 30 days; provider requesting multiple strengths of the same drug for dose titration — approval duration: 30 days; therapy supported by medical literature as standard of care — approval duration: 12 months. If medical necessity is not established the case should be denied based on the restrictions identified by drug class. |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.